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All diagnosed patients with type 1 diabetes and a large 
majority of patients with type 2 diabetes in most West-
ern countries are treated with blood glucose-lowering 
drugs. Data from nationwide prescription drug data-
bases can therefore be used to estimate prevalence and 
incidence of drug-treated diabetes and trends over time, 
although there are limitations of such data. 
 
ABOUT THE NORPD 
 
Every month since 2004, the Norwegian Institute of 
Public Health has received automatically generated da-
ta on prescriptions from all Norwegian pharmacies (1). 
NorPD contains information about all drugs prescribed 
(reimbursed or not) and dispensed at pharmacies to 
individual patients living outside institutions, i.e. 
ambulatory care. For patients in nursing homes and 
hospitals, the figures for drug use are included in the 
register at institution or department level, i.e. on an 
aggregated level. 
 The NorPD has a website for easy access to pre-
scription statistics in Norway (2). All patients with at 
least one prescription dispensed during a year are in-
cluded in the database. Reports on the number of users 
of a particular drug or drug group can be retrieved. 
Detailed information can be obtained by performing 
searches using the Anatomical Therapeutic Chemical 
(ATC) code, substance name or brand name. The data-
base is annually updated with data from the preceding 
year. Data from the NorPD are also published in an 
annual report (3). For research and e.g. surveillance 
purposes which are in accordance with the aims of the 
NorPD, further information is available upon request 
(4). 
 
TREATMENT WITH BLOOD GLUCOSE-
LOWERING DRUGS AS A PROXY FOR DIABETES 
 
Blood glucose-lowering drugs are classified in the 
ATC group A10 Drugs used in diabetes. The group is 
subdivided into Insulins and analogues (A10A) and 
Other blood glucose-lowering drugs (non-insulins, 
A10B) (5). 
 While many approaches of estimating the total 
number of individuals diagnosed with diabetes in a 
population are likely to have significant sources of 
error, data from nationwide prescription drug data-
bases can overcome problems of for example biased 
participation and limited sample sizes. 
 The use of dispensed drugs as proxy for diabetes 
will obviously result in an underestimation of the total 
number of diabetes patients in the population since a 
significant proportion of individuals with Type 2 dia-
betes is treated with lifestyle measures alone. Further-
more, the proportion of individuals with undiagnosed 
diabetes is considerable. 
 Classification of type 1 versus type 2 diabetes is 
challenging in a prescription database. In children, 
insulin use essentially indicates a diagnosis of type 1 
diabetes. In the older age groups, both patients with 
type 1 and type 2 diabetes may be treated with insulins.  
 
CALCULATING PREVALENCE AND INCIDENCE 
 
A simple NorPD search reveals that in 2012 approxi-
mately 161,000 individuals (3.2% of the population) 
had at least one prescription of a drug in ATC group 
A10 dispensed; the prevalence according to age groups 
and gender are shown in Figure 1. For insulins the 
number was 56,300 (1.1%) and for non-insulins 
124,900 (2.5%) (3). It is important to be aware of the 
fact that patients receiving both insulins (A10A) and 
another blood glucose-lowering drug (A10B), will 
only be counted once on an aggregated level (A10). 
Thus about 20,200 individuals had in 2012 received 
drugs from both subgroups. 
 While patients treated with non-insulins are most 
likely to suffer from Type 2 diabetes, individuals treat-
ed with insulins could suffer from either type 1 or type 
2 diabetes. For type 2 diabetes, drug treatment may be 
discontinued or intensified e.g. by adding insulin. It is 
therefore important to follow treatment of individuals 
over years. 
 Estimating the number of patients with type 1 or 
type 2 diabetes treated with blood glucose-lowering 
drugs requires a more sophisticated approach. In 
NorPD, different lengths of drug free period may be 
applied. For example, individuals who had at least one 
prescription of insulin dispensed during an observation 
year, but had no other blood glucose-lowering drugs in 
the two years period prior to the first prescription 
could be counted as prevalent users of insulin only, 
and thus possible type 1 diabetes patients. 
 There are also several methods for calculating the 
proportion of new users (incident users) being treated 
with insulins and analogues and/or other blood 
glucose-lowering drugs. The different approaches 
may, with limitations, indicate the number of new 
individuals with type 1 versus type 2 diabetes treated 
with drugs. 
 
RESEARCH INCLUDING DATA FROM THE NORPD 
 
Based on data from the NorPD from January 2004 to 
June 2005, the prevalence and incidence of drug-
treated diabetes in Norway have been studied (6). It 
was concluded that the NorPD provides a good esti-
mate of the number of patients diagnosed with diabetes 
who receive blood glucose-lowering drugs outside 
hospitals and nursing homes. 
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Alternative figure:  
 
 
Figure: Proportion of the population (prevalence) with at least one blood glucose-lowering drugs (A10), or at least one non-insulin (A10B) 
dispensed in 2012 according to age groups and gender.  Source: NorPD 
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Figure 1.  Proportion of the population (prevalence) with at least one blood glucose-lowering drug (A10) or non-insulins 
(A10B) dispensed in 2012 according to age groups and gender. Source: NorPD. 
 
 
 A European study including data from NorPD com-
pared the prevalence of diabetes in children across 
seven European countries, using prescription of blood 
glucose-lowering drugs as a proxy for diabetes. A 
varying frequency of type 1 diabetes in children and 
adolescents across Europe was shown. It was demon-
strated that it is possible to obtain similar information 
from different clinical databases within Europe, which 
would allow continuous monitoring of type 1 diabetes 
in children (7). 
 Data from NorPD has been linked to the Norwegian 
Childhood Diabetes Mellitus Registry to study the 
completeness of the information in the Registry. Using 
insulin prescriptions in the NorPD as reference, the 
detection rate of type 1 diabetes in the Norwegian 
Childhood Diabetes Mellitus Registry was estimated to 
be 91% (8). 
 
 
ON-GOING RESEARCH 
 
A working group with representatives from clinical 
practice and the Norwegian Institute of Public Health, 
supported by the Norwegian Diabetes Association, is 
analysing data from NorPD to describe time-trends in 
prevalence and incidence of diabetes treated with 
blood glucose-lowering drugs. This will contribute to 
an updated estimate of the total number of patients 
with diabetes in Norway. 
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